Media ReleasesEco Quest

View All Eco Quest News

EcoQuest, Cynata Therapeutics - CEO Presentation: Becoming a Next Generation Stem Cell Company

Stem Cell Field is Emerging

Analogous to monoclonal antibody enabling technologies in ‘80s and ‘90s which now have a therapeutic market value in excess of US$44.6b;

Commercial stem cell products are entering the market:
-  Prochymal (GvHD) – Osiris (USA)
-  Cartistem (Osteoarthritis) – Medipost/Dong-A (Korea);

Most stem cell companies attractively priced based on forward estimates;

Multiple products in Phase 2 and 3
-  Sector news flow
-  Creates opportunities for Cynata;

Big pharma partnering/M&A:
-  Teva/Mesoblast
-  Pfizer/Athersys
-  United Therapeutics/Pluristem
-  Novartis/Regenerex.

To view Presentation please download PDF below:

Download this document